drugset / Trial / NCT00946920
A Trial of Degarelix in Patients With Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.
Timeline
- Start
- 2009-06
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 480 mg | Subcutaneous |
| Comparator | Goserelin | Other / unclassified | 10.8 mg | Subcutaneous |